tolrestat   Click here for help

GtoPdb Ligand ID: 7404

Synonyms: Alredase® | AY-27,773 | AY-27773
Approved drug PDB Ligand
tolrestat is an approved drug
Compound class: Synthetic organic
Comment: Tolrestat is an aldose reductase inhibitor [1] that failed Phase 3 clinical trial in the US and never made it to the clinic. The manufacturer withdrew the drug from other markets due to toxicity concerns.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 3
Hydrogen bond donors 1
Rotatable bonds 6
Topological polar surface area 81.86
Molecular weight 357.06
XLogP 3.99
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES COc1ccc2c(c1C(F)(F)F)cccc2C(=S)N(CC(=O)O)C
Isomeric SMILES COc1ccc2c(c1C(F)(F)F)cccc2C(=S)N(CC(=O)O)C
InChI InChI=1S/C16H14F3NO3S/c1-20(8-13(21)22)15(24)11-5-3-4-10-9(11)6-7-12(23-2)14(10)16(17,18)19/h3-7H,8H2,1-2H3,(H,21,22)
InChI Key LUBHDINQXIHVLS-UHFFFAOYSA-N
No information available.
Summary of Clinical Use Click here for help
This drug was approved for the control of certain diabetic complications but was discontinued due to severe side effects.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
Tolrestat is an aldose reductase (AR) inhibitor. The AR AKR1B1 has been implicated in the development of diabetic complications as it catalyzes the reduction of glucose to sorbitol. AR inhibitors decrease the diabetes-associated accumulation of sorbitol in insulin insensitive tissues (such as lense cells, peripheral nerves and the renal glomerulus) which causes damage in these tissues and which leads to diabetic retinopathy, neuropathy and kidney damage [3].